A colloborative study with Zurich University of Applied Sciences(ZHAW)

Unlock the secrets to consistent excellence and scale-up success in monoclonal antibody (mAb) manufacturing, thanks to the dynamic collaboration between Thermo Fisher Scientific and the Zurich University of Applied Sciences (ZHAW).*

Successfully scaling up monoclonal antibody (mAb) production can involve overcoming many challenges. Developers need to maintain process productivity and protein quality throughout, while simultaneously maximizing efficiency and cost-effectiveness.

Central to achieving these goals is a robust, commercially available, scalable medium and feed platform. The Gibco™ Efficient-Pro™ Medium and Feeds System, which consists of a basal medium and two separate feeds (Feed 1 and Feed 2) for use with different CHO cell lines, has been specifically developed to optimize CHO protein bioproduction and support scale-up for a seamless transition to clinical and commercial manufacturing.

To demonstrate the scalability of the Efficient-Pro system, we collaborated with the Centre for Biochemical Engineering and Cell Cultivation Techniques at the Zurich University of Applied Sciences. In our study, using a fed-batch process with CHO-K1 cells, we evaluated the performance of the Gibco™ Efficient-Pro™ Medium and Feed 1 at three scales.

This comprehensive guide delves into how the Efficient-Pro Medium and Feed 1 can enable a seamless and rapid upstream process development. It significantly reduces both early-stage and late-stage development timelines, ensuring you stay ahead in the fast-paced world of biotherapeutics.

Our white paper also introduces you to the top-down approach, a strategy focused on designing a scaled-down development process that mimics key parameters of a large-scale process. Learn how this method, coupled with Efficient-Pro Medium and Feed 1, can maximize productivity and maintain consistent production levels and product quality across runs.

Download our white paper today and revolutionize your bioproduction process. Stay on the cutting edge of biotech industry developments with Thermo Fisher Scientific!

Figure 2. IgG titer. CHO-K1 cells in Efficient-Pro Medium and Feed 1 produced consistently similar IgG titers during scale-up, with titers of 4.5–4.8 g/L in the three Ambr 250 system runs, 5.2 g/L in the 3 L HyPerforma Glass Bioreactor, and 4.9 g/L in the 50 L DynaDrive S.U.B. No difference in titer was observed as a result of using either a bolus (B) or continuous (C) feeding strategy.

* ZHAW is a leading Swiss research institution with extensive expertise in life sciences and pharmaceuticals. ZHAW’s Centre for Biochemical Engineering and Cell Cultivation Techniques is renowned for its excellence in cell culture process development, backed by over 20 years of bioprocessing experience.